Table 1. Clinicopathological characteristics of the 117 patients.
| Sex | |
| Male | 77 (65.8%) |
| Female | 40 (34.2%) |
| Age (years) (range) | 61 (27–79) |
| Distance of tumor from AV (mm) (range) | 40 (0–80) |
| Baseline CEA >5 ng/ml | 35 (29.9%) |
| Clinical T category | |
| T2 | 1 (0.9%) |
| T3 | 105 (89.7%) |
| T4 | 11 (9.4%) |
| Clinical stage | |
| II | 55 (47.0%) |
| III | 62 (53.0%) |
| Histological type | |
| Well/moderate | 113 (96.6%) |
| poor | 4 (3.4%) |
| Operative procedure | |
| Sphincter preserving | 81 (69.2%) |
| Sphincter non-preserving | 36 (30.8%) |
| ypT category | |
| ypT0 | 12 (10.2%) |
| ypTis | 2 (1.7%) |
| ypT1 | 10 (8.6%) |
| ypT2 | 40 (34.2%) |
| ypT3 | 51 (43.6%) |
| ypT4 | 2 (1.7%) |
| ypN category | |
| ypN0 | 92 (78.6%) |
| ypN1 | 19 (16.2%) |
| ypN2 | 6 (5.2%) |
| Tumor regression grade | |
| TRG1 | 37 (31.6%) |
| TRG2 | 63 (53.8%) |
| TRG3 | 4 (3.4%) |
| TRG4 | 13 (11.2%) |
| Adjuvant chemotherapy | 42 (35.9%) |
Data are n (%) or median (range). AV, anal verge. CEA, carcinoembryonic antigen. CRT, chemoradiotherapy. TRG, tumor regression grade.